 |
|
|
| |
Efficacy and Safety of B/F/TAF in Hispanic/Latine Adults With HIV-1 Initiating First-Line Therapy: 5-Year Follow-up From Two Phase 3 Studies
|
| |
| |
AIDS 2024 July 20-26 Munich
Claudia Martorell1, Olayemi Osiyemi2, Mezgebe Berhe3, Lizette Santiago4, Christopher Rosero5, Fang Fang5, Nathan Unger5, Jason T Hindman5, Moti Ramgopal6
1The Research Institute, Springfield, MA, USA; 2Triple O Research Institute, West Palm Beach, FL, USA; 3North Texas Infectious Diseases Consultants, Dallas, TX, USA; 4HOPE Clinical Research, San Juan, Puerto Rico; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Midway Immunology and Research Center, Fort Pierce, FL, USA
SEE BELOW for Supplemtary materials: participants regional distribution, etc.
SEE BELOW for Supplemtary materials: participants regional distribution, metabolic, renal outcomes
|
| |
|
|
|
|
|
